Non-Small Cell Lung Cancer Market Industry Share, Growth, Segments and Forecast - 2031
The global non-small cell lung cancer market is growing at a CAGR of 9.6% during the forecast period (2024-2031). NSCLC is a type of cancer that is most common among smokers as well as non-smokers group of people. NSCLC in comparison to the other form of cancer called small cell lung cancer grows and spreads less aggressively. Therefore, NSCLC has a better chance of treatment with surgery, chemotherapy, and other medical treatments. The major factor propelling the growth of the NSCLC market includes evolving drug landscape for the treatment of NSCLC. The major factors that are augmenting the growth of the market are the rise in air pollution, smoking cigarettes, pipes, or cigars, being in exposure to asbestos, arsenic, chromium, beryllium, nickel, soot, or tar in the workplace, and being exposed to radiation. Around 84% of the tumor is non-small cell lung cancer and most of the advanced stage is treated with chemotherapy, targeted drugs, and/or immunotherapy.
Get Free Sample link @ https://www.omrglobal.com/request-sample/non-small-cell-lung-cancer-market
In addition to this, hereditary causes and being infected with HIV are another factor that drives the global non-small cell lung cancer diagnostics and therapeutics market. However, the high cost of drugs and treatment and the risk associated with it are some of the restraints that can challenge the growth of the market in the forecast period. Conversely rise in better chances of treatment with surgery, chemotherapy, and other medical treatments are estimated to be the opportunity for the market players. Moreover, the significant increase in the R&D activities supported by government organizations such as the American Lung Association, which has made support for lung cancer research its top priority, is also aiding with the growth of the market.
Full report of Non-Small Cell Lung Cancer Market available @ https://www.omrglobal.com/industry-reports/non-small-cell-lung-cancer-market
Impact of COVID-19 on the Global Non-Small Cell Lung Cancer Market
The global non-small lung cancer market is hardly hit by the COVID-19 pandemic since December 2019. Key industry therapy of non-small cell lung cancer includes chemotherapy, radiation therapy, surgery, and targeted therapy in top economies such as China, the US, and European Union. The COVID-19 pandemic in these major economies has led to delay in treatment across the globe. Moreover, the frequent visits to hospitals might considerably increase the risk of being infected due to which many patients themselves decided to delay the treatment. During the global pandemic, the 30-day mortality rate in patients with newly diagnosed NSCLC significantly increased with the pandemic from 25% before COVID-19 to 49% during COVID-19. However, the market will witness “W” shape recovery in near future owing to the increase in the number of patients who experienced a delay in treatment in major economies. The market will show a decline in share twice due to the most economies faced by the second wave. One of the growth opportunities includes the clinical guideline published by the National Institute for Health and Care Excellence (NICE) for the guidance of standard anticancer treatments to cancer patients with COVID-19 and to maximize the use of the available resources to sustain health services.
Segmental Outlook
The market is segmented based on type, therapy, diagnosis, and end-user. Based on the type segment, the market is segmented into adenocarcinomas, squamous cell carcinoma, large cell carcinomas, and others. Based on the therapy segment, the market is segmented into chemotherapy, targeted therapy, radiation therapy, surgery, cryosurgery, and others. Among these, the chemotherapy segment is anticipated to have significantly large shares during the forecast period. Based on the diagnosis segment, the market is segmented into CT scan, x-rays, sputum cytology, bronchoscopy, laboratory tests, thoracoscopy, and others. Further based on the end-user segment, the market is bifurcated into multispeciality hospitals and cancer research centers.
Reasons to Buying From us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/non-small-cell-lung-cancer-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.